RxDoctor Payments Data

Rebecca Rey, MD

Family Medicine · Pompano Beach, FLNPI 1649412313

Payments from drug & device makers

$4,006in general payments, 2019–2025

Across 207 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$638
  • Johnson & Johnson$352
  • Pfizer$242
  • Merck$167
  • Boehringer Ingelheim$164
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,88997%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,006 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,094
Medicare patients
120
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$106,382
MounjaroTirzepatide41$50,569
EliquisApixaban29$35,039
JardianceEmpagliflozin26$27,893
Repatha SureclickEvolocumab34$24,244
Praluent PenAlirocumab11$11,164
SynthroidLevothyroxine Sodium53$4,375
Rosuvastatin Calcium203$2,686
Levothyroxine Sodium164$2,292
Atorvastatin Calcium183$2,052
Losartan Potassium137$1,671
Amlodipine Besylate144$1,304
Methenamine Hippurate13$1,286
Metoprolol Succinate76$1,271
Duloxetine Hcl51$1,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,050$106,38282 claims
Lilly USA, LLCMounjaro$162$50,56941 claims
PfizerEliquis$242$35,03929 claims
Boehringer IngelheimJardiance$164$27,89326 claims
AbbVieSynthroid$24$4,37553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pompano Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →